Trial Profile
A Phase 1, Open-Label, Two-Part Study to Evaluate the Pharmacokinetics of Pomalidomide (CC-4047) in Hepatically Impaired Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2020
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary)
- Indications Amyloid light-chain amyloidosis; Brain cancer; Kaposi's sarcoma; Multiple myeloma; Myelofibrosis; Systemic scleroderma
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 25 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Apr 2013 New trial record